Cardiac Rhythm Disorders
Win Medica Pharmaceutical S.A. supports clinical research in atrial fibrillation, with a particular focus on restoring sinus rhythm in patients presenting with recent-onset or paroxysmal atrial fibrillation. The sponsored studies examine treatment options used in the Emergency Department and in patients with coronary artery disease and preserved left ventricular function.
- Cardioversion of paroxysmal atrial fibrillation
- Restoration of sinus rhythm
- Emergency Department arrhythmia management
The research activity in this area centers on antiarrhythmic treatment strategies relevant to acute rhythm control and clinical decision-making in patients with symptomatic atrial arrhythmias.
Antiarrhythmic Therapy
The sponsor’s portfolio includes studies of flecainide and amiodarone, reflecting interest in pharmacologic options for cardioversion and rhythm stabilization. Research also extends to combination approaches involving ranolazine alongside flecainide for recent-onset atrial fibrillation.
- Flecainide-based rhythm control
- Amiodarone comparator studies
- Combination antiarrhythmic regimens
These trials place emphasis on both effectiveness and safety within acute antiarrhythmic treatment pathways.
Arterial Hypertension
Win Medica Pharmaceutical S.A. is also active in arterial hypertension research, with studies evaluating fixed-dose antihypertensive therapy in patients requiring long-term blood pressure control. The therapeutic focus includes the use of irbesartan and amlodipine as a combined treatment option.
- Blood pressure management
- Fixed-dose combination therapy
- Irbesartan/amlodipine
This area reflects the sponsor’s involvement in cardiovascular medicine beyond rhythm disorders, with attention to chronic vascular disease treatment.
